Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Nat Rev Cancer. 2020 Jan;20(1):4-11. doi: 10.1038/s41568-019-0220-y. Epub 2019 Nov 28.
Brain metastasis, which commonly arises in patients with lung cancer, breast cancer and melanoma, is associated with poor survival outcomes and poses distinct clinical challenges. The brain microenvironment, with its unique cell types, anatomical structures, metabolic constraints and immune environment, differs drastically from microenvironments of extracranial lesions, imposing a distinct and profound selective pressure on tumour cells that, in turn, shapes the metastatic process and therapeutic responses. Accordingly, the study of brain metastasis could uncover new therapeutic targets and identify novel treatment approaches to address the unmet clinical need. Moreover, such efforts could provide insight into the biology of primary brain tumours, which face similar challenges to brain metastases of extracranial origin, and vice versa. However, the paucity of robust preclinical models of brain metastasis has severely limited such investigations, underscoring the importance of developing improved experimental models that holistically encompass the metastatic cascade and/or brain microenvironment. In this Viewpoint, we asked four leading experts to provide their opinions on these important aspects of brain metastasis biology and management.
脑转移,常见于肺癌、乳腺癌和黑色素瘤患者,与不良的生存结局相关,并带来独特的临床挑战。脑微环境,具有独特的细胞类型、解剖结构、代谢限制和免疫环境,与颅外病变的微环境有很大的不同,对肿瘤细胞施加了独特而深远的选择压力,进而影响转移过程和治疗反应。因此,研究脑转移可以揭示新的治疗靶点,并确定新的治疗方法来满足未满足的临床需求。此外,这些努力可以深入了解原发性脑肿瘤的生物学特性,因为它们面临着与颅外起源的脑转移相同的挑战,反之亦然。然而,脑转移的稳健临床前模型的缺乏严重限制了这些研究,这突显了开发改进的实验模型的重要性,这些模型可以全面涵盖转移级联和/或脑微环境。在本观点中,我们邀请了四位专家就脑转移生物学和管理的这些重要方面提供意见。